BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...targeting GBA, as well as six targeting LRRK2...
...population straight away. For example, most companies targeting LRRK2...
...Ventures. TARGETSGBA (GCase) – Glucosylceramidase βLRRK2 - Leucine-rich repeat kinase 2 SNCA...
BioCentury | Sep 11, 2020
Deals

Data Bytes: upfront tally shows 2020’s dealmakers playing catch-up

...years.For example, Denali Therapeutics Inc. (NASDAQ:DNLI) entered a deal with Biogen Inc. (NASDAQ:BIIB) to develop an LRRK2...
BioCentury | Aug 8, 2020
Deals

Data Bytes: taking stock of Biogen’s pipeline as aducanumab timeline comes into focus

...Inc. (NASDAQ:DNLI) gave Biogen the newest addition to its pipeline -- DNL151, a small molecule LRRK2...
BioCentury | Aug 7, 2020
Deals

Data Bytes: Biogen marks Denali’s biggest deal yet

...in milestones, plus tiered royalties on ex-U.S. and ex-China sales of DNL151, a small molecule LRRK2...
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...DNL151 in the U.S. and China, with Biogen responsible for commercialization elsewhere. The small molecule LRRK2...
...The partners are planning two studies, one in Parkinson’s patients with a kinase-activating mutation in LRRK2...
...factor 2B IDS -- Iduronate 2-sulfatase LRRK2 -- Leucine-rich repeat kinase 2 Virginia Li, Associate Editor DNL151 Biogen Inc. Denali Therapeutics Inc. Leucine-rich repeat kinase 2 (LRRK2...
BioCentury | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

...$5.16 (29%) to $22.74 after presenting safety and biomarker data for its two small molecule LRRK2...
...OTCQX:RHHBY). At least one other LRRK2 inhibitor has progressed to Phase I for PD: the LRRK2-targeting...
...late 2020. Targets: IDS - Iduronate 2-sulfatase; LRRK2 - leucine-rich repeat kinase 2 Hongjiang Li, Staff Writer DNL151 DNL201 Denali Therapeutics Inc. Leucine-rich repeat kinase 2 (LRRK2) Iduronate...
BioCentury | Nov 13, 2019
Company News

Merck acquiring Avalon lysosomal disorder play Calporta

...of confidence,” Madigan said. The pharma has one internal program in the autophagy pathway, a LRRK2...
...announce news about one of them in the next couple of months. Targets: LRRK2 - Leucine-rich repeat kinase 2...
BioCentury | Oct 24, 2019

GCase activator reduces α-synuclein in mouse, patient-derived models of PD

...neurons from PD patients with mutations in GCase or in PD-linked genes parkin (PARK2), leucine-rich repeat kinase 2 (LRRK2...
BioCentury | Aug 23, 2018
Translation in Brief

LRRK2 looming larger

...LRRK2 activity and idiopathic forms of Parkinson’s disease, further broadening the potential patient population for LRRK2...
...including two clinical compounds from Denali Therapeutics Inc. (NASDAQ: DNLI). Multiple gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2...
...assay to detect LRRK2 kinase activity by measuring autophosphorylation of LRRK2 at serine 1292 and LRRK2...
BioCentury | Jul 27, 2018
Company News

GSK, 23andMe partner on target, drug discovery

...23andMe, either partner can contribute early stage programs to the collaboration, and GSK's preclinical leucine-rich repeat kinase 2 (LRRK2...
...NYSE:GSK), London, U.K. 23andMe Inc., Mountain View, Calif. Business: Genomics, Neurology, Other Jennie Walters 23andMe Inc. GlaxoSmithKline plc Leucine-rich repeat kinase 2 (LRRK2...
Items per page:
1 - 10 of 61